Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Loss of heterozygosity on chromosome arm 16q in breast cancer: clinical, molecular and statistical approaches

Authors: A-M Cleton-Jansen, HM van Beerendonk, NT ter Haar, PHC Eilers, HC van Houwelingen, BA Bonsing, VTHBM Smit, G-JB van Ommen, CJ Cornelisse

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

Loss of heterozygosity (LOH) on the long arm of chromosome 16 is one of the most frequent genetic events in breast cancer, occurring in at least 50% of the breast cancer cases. It is one of the earliest genetic events, occurring already in the pre-invasive stage, in ductal carcinoma in situ. Our study on flow-sorted tumour populations shows that chromosome 16q loss occurs in the DNA diploid sub-population of tumour cells, before aneuploidization, which is also indicative of a role in early tumorigenesis. …
Metadata
Title
Loss of heterozygosity on chromosome arm 16q in breast cancer: clinical, molecular and statistical approaches
Authors
A-M Cleton-Jansen
HM van Beerendonk
NT ter Haar
PHC Eilers
HC van Houwelingen
BA Bonsing
VTHBM Smit
G-JB van Ommen
CJ Cornelisse
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr114

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Meeting abstract

Modulation of ATM gene expression in a murine mammary epithelial cell line

Oral presentation

p53-mediated apoptosis and genomic instability syndromes

Meeting abstract

p16INK4A as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy

Meeting abstract

Promising method for DNA extraction from paraffin embedded archive material

Meeting abstract

HRAS1 minisatellite alleles and breast cancer in Spanish women under age forty years

Oral presentation

The importance of breast cancer research from a patient's view: the voices and visions of advocates
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits